Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-25T08:18:42.401Z Has data issue: false hasContentIssue false

A.3 The Canadian registry for amyloidosis research: a national multi-disciplinary registry for real-world evidence

Published online by Cambridge University Press:  05 June 2023

N Fine
Affiliation:
(Calgary)
V Hodgkinson
Affiliation:
(Calgary)*
D Reece
Affiliation:
(Toronto)
D Delgato
Affiliation:
(Toronto)
C Venner
Affiliation:
(Edmonton)
S Baker
Affiliation:
(Hamilton)
R Massie
Affiliation:
(Montreal)
K Boyartchuk
Affiliation:
(Calgary)
G Jewett
Affiliation:
(Calgary)
M Mezei
Affiliation:
(Vancouver)
C Hahn
Affiliation:
(Calgary)
K Dares
Affiliation:
(Toronto)
M Davis
Affiliation:
(Vancouver)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: The Canadian Registry for Amyloidosis Research (CRAR) is a nationwide disease registry of transthyretin (ATTR) and light-chain (AL) amyloidosis. Recent advances in disease-modifying therapy have improved prognosis, however there is a critical need for real-world evidence to address knowledge gaps, particularly longer-term therapeutic outcomes and surveillance strategies. Methods: A multi-stakeholder process was undertaken to develop a consensus dataset for ATTR- and AL-amyloidosis. This process included surveys to rank the importance of potential data items, and a consensus meeting of the CRAR steering committee, (comprised of multidisciplinary clinical experts, and patient organization representatives). Patients and patient organizations supported the development and implementation of a patient-reported dataset. Results: Consensus data items include disease onset, progression, severity, treatments, and outcomes, as well as patient-reported outcomes. Both prospective and retrospective (including deceased) patient cohorts are included. Further baseline data will be presented on an initial cohort of patients. Conclusions: CRAR has been established to collect a longitudinal, multidisciplinary dataset that will evaluate amyloidosis care and outcomes. CRAR has launched at multiple specialty amyloidosis centers nationally and is continually expanding. The growth of this program will promote opportunities to assess real-world safety and efficacy and inform the cost-effectiveness of therapies while supporting patient recruitment for research.

Type
Abstracts
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation